AAIC 2025 Abstract
The utility of phosphorylated Tau‐217 in discriminating chronic traumatic encephalopathy and Alzheimer’s disease in postmortem cerebral spinal fluid and serum
By William S Cole-French, Petra Ypsilantis, Guglielmo Di Molfetta, Show 19 more authorsThor D. Stein
Study in peopleBiomarkers
Abstract
Background: Phosphorylated tau ( p ‐tau)217 has emerged as the optimal blood‐based biomarker for assessing Alzheimer’s disease (AD) pathology in vivo . However, the ability of p ‐tau217 to detect other neurodegenerative diseases such as chronic traumatic encephalopathy (CTE) is unknown.
